Liquidia price target raised to $32 from $16 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Liquidia to $32 from $16 and keeps a Buy rating on the shares. The analyst believes the FDA’s inclusion of the pulmonary hypertension associated with interstitial lung disease indication for review with the tentatively approved new drug application for Yutrepia in pulmonary arterial hypertension reflects a critical component to facilitate near-term commercial growth for Yutrepia.